Multiple patents contribute to a robust portfolio; however,
each patent that issues can potentially become a landmine to
another
Time is often money in the pharmaceutical industry, and this is
particularly true regarding patents that protect the exclusivity of
FDA-approved products. US patents have a term of 20 years. But
because the FDA approval process for pharmaceuticals can take
several years, federal law, specifically 35 U.S.C. § 156,
allows restoration of time lost to regulatory approval by allowing
patentees to apply for up to five years of patent term extension
(PTE), which is added to the end of a patent term. Those additional
years often coincide with peak sales of the approved drug, making
the PTE period the most profitable—and meaning that properly
protecting that PTE period can be worth billions of dollars.
Because there is only one opportunity to obtain PTE, it is critical
to not only select the right patent to extend, but also to make
sure that the